Tagged with PR

Serbia Nenad Markovic, director of fast-growing, family-run pharmaceutical company ADOC in Serbia, sheds light on the organisation’s rapid and consistent growth, the ADOC stamp of approval and why the road to EU membership will be a smooth one for ADOC. What are ADOC’s current operations in Serbia? “We are very happy…

Serbia Predrag Lukic, general manager of Amicus, a new and exciting bridging service for MNCs looking to expand into Serbia and the Balkans, reveals the keys to accessing the region and how best to take advantage of the professional talent pool in Serbia. Through careful study of the market and by…

Lithuania Rytis Naginevičius, director at software development and market analysis specialist SoftDent discusses the company’s targeted solutions for the pharmaceutical and medical industries. You have a quite unusual profile with no healthcare background before you founded SoftDent in 1998. What are the needs that you identified that made you switch to…

Serbia CEO of Health Watch Swiss and general manager at Protonmed Serbia, Themis Moustakas has built a quality company thanks to Swiss practices and an entrepreneurial spirit over the last four years. Moustakas reveals how to best approach the mercurial Serbian market, the trick to bidding on government tenders, and how…

Canada Dr. John Sampalis, CEO of JSS talks about the impact that changes in the global R&D landscape have had on JSS, the role technology is playing in running an efficient clinical trial program and the company’s next exciting move into the US. John, what have been the main milestones of…

Canada Dr. Janice E. Parente, president and founder of ethica CRO, explains what led her company to work with pharmaceutical companies internationally and how ethica CRO’s accreditations are an emblem of excellence. Furthermore, she presents ideas on how Canada could be more competitive in terms of R&D globally, by converting its…

Switzerland Jonathan Koch, group president R&D Laboratories at Swiss-based CRO, Covance, explains how the integration process with LabCorb has progressed over the last two years, Covance’s embrace of digitally disruptive technologies, and becoming a “flexible service provider.” Two years on from LabCorp’s headline-making acquisition of Covance, how has the integration process…

Switzerland Marc Funk, COO of Swiss-headquartered product development service specialist, Lonza, discusses the company’s remarkable recent fortunes, how it is implementing innovative efficiency improvements, and answers the question, “why Switzerland?”   We aspire to move the company and the relationship with our customers from being a functional service provider to the strategic partner…

Lithuania Darius Sinkevičius, chairman of the board at the Lithuanian Association of Generic Pharmaceuticals Manufacturers (VGA), explains the main trends impacting the generic pharmaceutical industry in the country as well as the role of off-patent medicines in creating savings for the Lithuanian healthcare system. Can you give to our international audience…

Switzerland In an exclusive interview, Bruno Strigini, global CEO of Novartis Oncology, discusses the logic of the company’s separate oncology business unit, the significance of US FDA approval for the new CAR-T cell therapy, Kymriah, and the issues around pricing for this revolutionary treatment.   * Please note that this interview was…

Switzerland Oliver Rinner, CEO and founder of Biognosys, provides a fascinating account of the company’s unique business model and explains how its technical research into proteomics and cell expression is likely to be even more successful despite continuous technological developments. Biognosys – a proteomics focused company – was initially founded as…

Poland Irena Rej, president of the Polish Pharmaceutical Chamber, Farmacja Polska, discusses the trends of the domestic pharmaceutical market and the recent changes to improve the introduction of innovative products. Furthermore, she highlights the strengths of the local OTC industry and the chamber’s role in facilitating active dialogue with key stakeholders…